Pomerantz Law Firm Issues Investor Alert Regarding Pacira Biosciences, Class Action Filed

Investor Alert: Pacira Biosciences, Inc. Class Action Lawsuit

The Pomerantz Law Firm has recently declared a class action lawsuit against Pacira Biosciences, Inc. (NASDAQ: PCRX). This comes after significant losses have been reported by investors who purchased shares during the specified class period. Those who believe they may have been affected are encouraged to voice their concerns and to reach out to the firm for further guidance.

Key Details of the Lawsuit

The class action highlights alleged securities fraud and unlawful business practices by Pacira and certain members of its leadership. Investors with losses are particularly urged to make contact with Danielle Peyton at the law firm, providing essential personal information such as mailing address, phone number, and the number of shares bought. The deadline for those affected to formally request to be appointed as a Lead Plaintiff is March 14, 2025.

Furthermore, a copy of the complaint can be accessed through the Pomerantz Law Firm's official site. This lawsuit was initiated following a major event on August 9, 2024, when the U.S. District Court for the District of New Jersey invalidated Pacira’s '495 patent. This patent protected its innovative non-opioid pain treatment Exparel. The court’s decision, based on criteria of obviousness and anticipation, caused Pacira's stock to plummet by $10.66 per share, marking a drastic decline of 47.67%, closing at $11.70.

Background of Pomerantz Law Firm

Established over 85 years ago by Abraham L. Pomerantz, a recognized pioneer in the realm of securities class actions, the Pomerantz Law Firm has built a strong reputation in handling corporate securities and antitrust class litigation. They are often hailed as a leader due to their extensive experience and successful track record of securing remarkable settlements for victims of corporate wrongdoings.

Through various multimillion-dollar recoveries for class members, Pomerantz continues to uphold its commitment to advocating for the rights of those affected by fraudulent securities practices. Investors are urged to act swiftly as deadlines approach. For comprehensive details about the class action and to understand one’s rights, individuals are encouraged to visit www.pomerantzlaw.com.

Next Steps for Investors

For investors who have suffered losses in their investments with Pacira Biosciences, now is the time to evaluate your situation. Engage with Pomerantz LLP if you believe you may be eligible to participate in this class action. Such actions not only provide potential recovery of losses but also send a strong message against corporate misconduct within the biotech field. Each investor's voice counts, and collective action like this plays a crucial role in corporate accountability.

Make your voice heard and consider your options carefully; you may have grounds for significant legal actions regarding your investments.

Disclaimer: This information does not constitute legal advice and is for informational purposes only. Prior settlements do not guarantee similar outcomes in this case.